Antonio Villaverde

List of Publications by Year
in descending order

342 papers	11,239 citations	31976 53 h-index	49909 87 g-index
354 all docs	354 docs citations	354 times ranked	8458 citing authors

#	Article	IF	Citations
1	Microbial factories for recombinant pharmaceuticals. Microbial Cell Factories, 2009, 8, 17.	4.0	349
2	Protein quality in bacterial inclusion bodies. Trends in Biotechnology, 2006, 24, 179-185.	9.3	310
3	Protein aggregation in recombinant bacteria: biological role of inclusion bodies. Biotechnology Letters, 2003, 25, 1385-1395.	2.2	276
4	Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microbial Cell Factories, 2008, 7, 11.	4.0	269
5	Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microbial Cell Factories, 2005, 4, 27.	4.0	266
6	Recombinant pharmaceuticals from microbial cells: a 2015 update. Microbial Cell Factories, 2016, 15, 33.	4.0	265
7	Biomedical applications of distally controlled magnetic nanoparticles. Trends in Biotechnology, 2009, 27, 468-476.	9.3	257
8	Amyloid-like Properties of Bacterial Inclusion Bodies. Journal of Molecular Biology, 2005, 347, 1025-1037.	4.2	217
9	Construction and deconstruction of bacterial inclusion bodies. Journal of Biotechnology, 2002, 96, 3-12.	3.8	191
10	The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnology and Bioengineering, 2007, 96, 1101-1106.	3.3	189
11	Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. Microbial Cell Factories, 2015, 14, 57.	4.0	178
12	Bacterial inclusion bodies: making gold from waste. Trends in Biotechnology, 2012, 30, 65-70.	9.3	157
13	Coevolution of cells and viruses in a persistent infection of foot-and-mouth disease virus in cell culture. Journal of Virology, 1988, 62, 2050-2058.	3.4	146
14	Bacterial Inclusion Bodies: Discovering Their Better Half. Trends in Biochemical Sciences, 2017, 42, 726-737.	7.5	134
15	Protein aggregation as bacterial inclusion bodies is reversible. FEBS Letters, 2001, 489, 29-33.	2.8	129
16	Recombinant protein solubilityâ€"does more mean better?. Nature Biotechnology, 2007, 25, 718-720.	17.5	119
17	Fine architecture of bacterial inclusion bodies. FEBS Letters, 2000, 471, 7-11.	2.8	118
18	Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnology Advances, 2013, 31, 140-153.	11.7	116

#	Article	IF	Citations
19	Nanostructured bacterial materials for innovative medicines. Trends in Microbiology, 2010, 18, 423-430.	7.7	107
20	Localization of Chaperones DnaK and GroEL in Bacterial Inclusion Bodies. Journal of Bacteriology, 2005, 187, 3599-3601.	2.2	106
21	Localization of Functional Polypeptides in Bacterial Inclusion Bodies. Applied and Environmental Microbiology, 2007, 73, 289-294.	3.1	102
22	Optimized release of recombinant proteins by ultrasonication ofE. coli cells. , 1998, 58, 536-540.		99
23	Protein-Based Therapeutic Killing for Cancer Therapies. Trends in Biotechnology, 2018, 36, 318-335.	9.3	98
24	<i>In Vivo</i> Architectonic Stability of Fully <i>de Novo</i> Designed Protein-Only Nanoparticles. ACS Nano, 2014, 8, 4166-4176.	14.6	89
25	Divergent Genetic Control of Protein Solubility and Conformational Quality in Escherichia coli. Journal of Molecular Biology, 2007, 374, 195-205.	4.2	85
26	Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends in Biotechnology, 2008, 26, 267-275.	9.3	85
27	Plasmid maintenance inEscherichia coli recombinant cultures is dramatically, steadily, and specifically influenced by features of the encoded proteins. , 1998, 58, 625-632.		84
28	Side effects of chaperone gene co-expression in recombinant protein production. Microbial Cell Factories, 2010, 9, 64.	4.0	84
29	Role of molecular chaperones in inclusion body formation. FEBS Letters, 2003, 537, 215-221.	2.8	83
30	Bacterial cell factories for recombinant protein production; expanding the catalogue. Microbial Cell Factories, 2013, 12, 113.	4.0	83
31	Bacterial inclusion bodies are industrially exploitable amyloids. FEMS Microbiology Reviews, 2019, 43, 53-72.	8.6	77
32	Peptide-mediated DNA condensation for non-viral gene therapy. Biotechnology Advances, 2009, 27, 432-438.	11.7	73
33	Surface Cell Growth Engineering Assisted by a Novel Bacterial Nanomaterial. Advanced Materials, 2009, 21, 4249-4253.	21.0	73
34	Isolation of cell-free bacterial inclusion bodies. Microbial Cell Factories, 2010, 9, 71.	4.0	72
35	Nanostructured antimicrobial peptides: The last push towards clinics. Biotechnology Advances, 2020, 44, 107603.	11.7	71
36	Environmental quality of mussel farms in the Vigo estuary: Pollution by PAHs, origin and effects on reproduction. Environmental Pollution, 2011, 159, 250-265.	7.5	70

#	Article	IF	Citations
37	Fine regulation of cI857-controlled gene expression in continuous culture of recombinant Escherichia coli by temperature. Applied and Environmental Microbiology, 1993, 59, 3485-3487.	3.1	69
38	Learning about protein solubility from bacterial inclusion bodies. Microbial Cell Factories, 2009, 8, 4.	4.0	68
39	Biological role of bacterial inclusion bodies: a model for amyloid aggregation. FEBS Journal, 2011, 278, 2419-2427.	4.7	68
40	The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials, 2010, 31, 5805-5812.	11.4	67
41	Functional Inclusion Bodies Produced in Bacteria as Naturally Occurring Nanopills for Advanced Cell Therapies. Advanced Materials, 2012, 24, 1742-1747.	21.0	67
42	BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS. Biotechnology Advances, 2015, 33, 277-287.	11.7	66
43	Dynamics of in vivo protein aggregation: building inclusion bodies in recombinant bacteria. FEMS Microbiology Letters, 1998, 169, 9-15.	1.8	65
44	Systems metabolic engineering, industrial biotechnology and microbial cell factories. Microbial Cell Factories, 2012, 11, 156.	4.0	65
45	Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. Biomaterials, 2012, 33, 8714-8722.	11.4	65
46	Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies. Acta Biomaterialia, 2013, 9, 6134-6142.	8.3	65
47	Towards protein-based viral mimetics for cancer therapies. Trends in Biotechnology, 2015, 33, 253-258.	9.3	65
48	Selective depletion of metastatic stem cells as therapy for human colorectal cancer. EMBO Molecular Medicine, 2018, 10, .	6.9	64
49	The position of the heterologous domain can influence the solubility and proteolysis of Î²-galactosidase fusion proteins in E. coli. Journal of Biotechnology, 1996, 48, 191-200.	3.8	63
50	Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. Nanotechnology, 2010, 21, 205101.	2.6	62
51	Dynamics of in vivo protein aggregation: building inclusion bodies in recombinant bacteria. FEMS Microbiology Letters, 1998, 169, 9-15.	1.8	61
52	Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles. International Journal of Nanomedicine, 2012, 7, 4533.	6.7	61
53	Bottomâ€Up Instructive Quality Control in the Biofabrication of Smart Protein Materials. Advanced Materials, 2015, 27, 7816-7822.	21.0	61
54	Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine, 2010, 5, 259-268.	3.3	59

#	Article	IF	Citations
55	Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs. Journal of Controlled Release, 2018, 274, 81-92.	9.9	55
56	Improved Mimicry of a Foot-and-Mouth Disease Virus Antigenic Site by a Viral Peptide Displayed on Î²-Galactosidase Surface. Bio/technology, 1995, 13, 801-804.	1.5	52
57	Packaging protein drugs as bacterial inclusion bodies for therapeutic applications. Microbial Cell Factories, 2012, 11, 76.	4.0	52
58	Modular protein engineering for non-viral gene therapy. Trends in Biotechnology, 2004, 22, 371-377.	9.3	50
59	Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy. Critical Reviews in Biotechnology, 2015, 35, 209-221.	9.0	50
60	Î²-Galactosidase Enzymatic Activity as a Molecular Probe to Detect Specific Antibodies. Journal of Biological Chemistry, 1996, 271, 21251-21256.	3.4	49
61	Engineering of solvent-exposed loops inEscherichia coliÎ²-galactosidase. FEBS Letters, 1998, 434, 23-27.	2.8	49
62	Role of the chaperone DnaK in protein solubility and conformational quality in inclusion body-formingEscherichia colicells. FEMS Microbiology Letters, 2007, 273, 187-195.	1.8	49
63	Assembly of histidine-rich protein materials controlled through divalent cations. Acta Biomaterialia, 2019, 83, 257-264.	8.3	49
64	Nanotechnology, bionanotechnology and microbial cell factories. Microbial Cell Factories, 2010, 9, 53.	4.0	48
65	Nanostructured toxins for the selective destruction of drug-resistant human CXCR4+ colorectal cancer stem cells. Journal of Controlled Release, 2020, 320, 96-104.	9.9	48
66	Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. Microbial Cell Factories, 2011, 10, 101.	4.0	47
67	Influence of growth temperature on the production of antibody Fab fragments in different microbes: A host comparative analysis. Biotechnology Progress, 2011, 27, 38-46.	2.6	46
68	Fixation of mutations at the VP1 gene of foot-and-mouth disease virus. Can quasispecies define a transient molecular clock?. Gene, 1991, 103, 147-153.	2.2	44
69	Allosteric enzymes as biosensors for molecular diagnosis. FEBS Letters, 2003, 554, 169-172.	2.8	44
70	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB Journal, 2015, 29, 464-476.	0.5	43
71	Production of functional inclusion bodies in endotoxin-free Escherichia coli. Applied Microbiology and Biotechnology, 2014, 98, 9229-9238.	3.6	42
72	Functional protein aggregates: just the tip of the iceberg. Nanomedicine, 2015, 10, 2881-2891.	3.3	42

#	Article	IF	Citations
73	Nanostructured recombinant cytokines: A highly stable alternative to short-lived prophylactics. Biomaterials, 2016, 107, 102-114.	11.4	42
74	Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia, 2016, 43, 230-239.	8.3	42
75	Divalent Cations: A Molecular Glue for Protein Materials. Trends in Biochemical Sciences, 2020, 45, 992-1003.	7.5	42
76	Yield, solubility and conformational quality of soluble proteins are not simultaneously favored in recombinant <i>Escherichia coli</i>. Biotechnology and Bioengineering, 2008, 101, 1353-1358.	3.3	41
77	Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discovery Today, 2008, 13, 1067-1074.	6.4	41
78	Bioadhesiveness and efficient mechanotransduction stimuli synergistically provided by bacterial inclusion bodies as scaffolds for tissue engineering. Nanomedicine, 2012, 7, 79-93.	3.3	40
79	Multifunctional Nanovesicle-Bioactive Conjugates Prepared by a One-Step Scalable Method Using CO₂-Expanded Solvents. Nano Letters, 2013, 13, 3766-3774.	9.1	40
80	Î±â€Galactosidaseâ€A Loadedâ€Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials, 2016, 5, 829-840.	7.6	40
81	Selective CXCR4⁺ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin. Small, 2018, 14, e1800665.	10.0	40
82	Engineering Secretory Amyloids for Remote and Highly Selective Destruction of Metastatic Foci. Advanced Materials, 2020, 32, e1907348.	21.0	40
83	Post-production protein stability: trouble beyond the cell factory. Microbial Cell Factories, 2011, 10, 60.	4.0	39
84	An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. Journal of Hematology and Oncology, 2020, 13, 36.	17.0	39
85	The chaperone DnaK controls the fractioning of functional protein between soluble and insoluble cell fractions in inclusion body-forming cells. Microbial Cell Factories, 2006, 5, 26.	4.0	38
86	Modular Protein Engineering in Emerging Cancer Therapies. Current Pharmaceutical Design, 2009, 15, 893-916.	1.9	38
87	Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles. International Journal of Pharmaceutics, 2014, 473, 286-295.	5.2	38
88	The Functional Quality of Soluble Recombinant Polypeptides Produced in Escherichia coli Is Defined by a Wide Conformational Spectrum. Applied and Environmental Microbiology, 2008, 74, 7431-7433.	3.1	37
89	Evolution of cellular ATP concentration after UV-mediated induction of SOS system in Escherichiacoli. Biochemical and Biophysical Research Communications, 1983, 117, 556-561.	2.1	36
90	Limitedin VivoProteolysis of Aggregated Proteins. Biochemical and Biophysical Research Communications, 1997, 237, 325-330.	2.1	36

#	Article	IF	Citations
91	Proteolytic digestion of bacterial inclusion body proteins during dynamic transition between soluble and insoluble forms. BBA - Proteins and Proteomics, 1999, 1434, 170-176.	2.1	36
92	Cellular uptake and intracellular fate of protein releasing bacterial amyloids in mammalian cells. Soft Matter, 2016, 12, 3451-3460.	2.7	36
93	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. Haematologica, 2020, 105, 741-753.	3.5	36
94	Artificial Inclusion Bodies for Clinical Development. Advanced Science, 2020, 7, 1902420.	11.2	36
95	Engineering Regulable Escherichia coliÎ²-Galactosidases as Biosensors for Anti-HIV Antibody Detection in Human Sera. Journal of Biological Chemistry, 2001, 276, 40087-40095.	3.4	35
96	Folding of a misfolding-prone Î²-galactosidase in absence of DnaK. Biotechnology and Bioengineering, 2005, 90, 869-875.	3.3	35
97	Bacterial inclusion bodies are cytotoxic in vivo in absence of functional chaperones DnaK or GroEL. Journal of Biotechnology, 2005, 118, 406-412.	3.8	35
98	Improving protein delivery of fibroblast growth factor-2 from bacterial inclusion bodies used as cell culture substrates. Acta Biomaterialia, 2014, 10, 1354-1359.	8.3	35
99	Insights on the emerging biotechnology of histidine-rich peptides. Biotechnology Advances, 2022, 54, 107817.	11.7	35
100	Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4 + colorectal cancer models. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1987-1996.	3.3	34
101	Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Advanced Science, 2019, 6, 1900849.	11.2	34
102	Enhanced production of pL-controlled recombinant proteins and plasmid stability in Escherichia coli RecA+ strains. Journal of Biotechnology, 1993, 29, 299-306.	3.8	33
103	Secretion-dependent proteolysis of heterologous protein by recombinantEscherichia coli is connected to an increased activity of the energy-generating dissimilatory pathway. , 1999, 66, 61-67.		33
104	Engineering nuclear localization signals in modular protein vehicles for gene therapy. Biochemical and Biophysical Research Communications, 2003, 304, 625-631.	2.1	33
105	Recombinant protein materials for bioengineering and nanomedicine. Nanomedicine, 2014, 9, 2817-2828.	3.3	33
106	Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector. BMC Neuroscience, 2006, 7, 35.	1.9	32
107	Two-Dimensional Microscale Engineering of Protein-Based Nanoparticles for Cell Guidance. ACS Nano, 2013, 7, 4774-4784.	14.6	32
108	Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories, 2016, 15, 166.	4.0	32

#	Article	IF	Citations
109	Peptideâ€Based Nanostructured Materials with Intrinsic Proapoptotic Activities in CXCR4⁺ Solid Tumors. Advanced Functional Materials, 2017, 27, 1700919.	14.9	32
110	A new approach to obtain pure and active proteins from Lactococcus lactis protein aggregates. Scientific Reports, 2018, 8, 13917.	3.3	32
111	The expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response inEscherichia coli. , 1998, 60, 551-559.		31
112	Lon and ClpP proteases participate in the physiological disintegration of bacterial inclusion bodies. Journal of Biotechnology, 2005, 119, 163-171.	3.8	31
113	Exploiting viral cell-targeting abilities in a single polypeptide, non-infectious, recombinant vehicle for integrin-mediated DNA delivery and gene expression. , 2000, 68, 689-696.		30
114	Molecular Organization of Proteinâ€"DNA Complexes for Cell-Targeted DNA Delivery. Biochemical and Biophysical Research Communications, 2000, 278, 455-461.	2.1	30
115	Release of targeted protein nanoparticles from functional bacterial amyloids: A death star-like approach. Journal of Controlled Release, 2018, 279, 29-39.	9.9	30
116	In situ protein folding and activation in bacterial inclusion bodies. Biotechnology and Bioengineering, 2008, 100, 797-802.	3.3	29
117	Engineering building blocks for self-assembling protein nanoparticles. Microbial Cell Factories, 2010, 9, 101.	4.0	29
118	Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. Scientific Reports, 2016, 6, 35765.	3.3	28
119	3D gene of foot-and-mouth disease virus. Journal of Molecular Biology, 1988, 204, 771-776.	4.2	27
120	Sheltering DNA in self-organizing, protein-only nano-shells as artificial viruses for gene delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 535-541.	3.3	27
121	Insertional protein engineering for analytical molecular sensing. Microbial Cell Factories, 2006, 5, 15.	4.0	26
122	A nanostructured bacterial bioscaffold for the sustained bottom-up delivery of protein drugs. Nanomedicine, 2013, 8, 1587-1599.	3.3	26
123	Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1241-1251.	3.3	26
124	Protein-only, antimicrobial peptide-containing recombinant nanoparticles with inherent built-in antibacterial activity. Acta Biomaterialia, 2017, 60, 256-263.	8.3	26
125	Control of Escherichia coli growth rate through cell density. Microbiological Research, 2002, 157, 257-265.	5.3	25
126	Fast electrochemical detection of anti-HIV antibodies: Coupling allosteric enzymes and disk microelectrode arrays. Analytica Chimica Acta, 2009, 641, 1-6.	5.4	25

#	Article	IF	Citations
127	Overexpression of the Immunoreceptor CD300f Has a Neuroprotective Role in a Model of Acute Brain Injury. Brain Pathology, 2012, 22, 318-328.	4.1	25
128	Microbial biofabrication for nanomedicine: biomaterials, nanoparticles and beyond. Nanomedicine, 2013, 8, 1895-1898.	3.3	25
129	Expanding the recombinant protein quality in Lactococcus lactis. Microbial Cell Factories, 2014, 13, 167.	4.0	25
130	Topographically targeted osteogenesis of mesenchymal stem cells stimulated by inclusion bodies attached to polycaprolactone surfaces. Nanomedicine, 2014, 9, 207-220.	3.3	25
131	Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles. Pharmaceutics, 2020, 12, 1004.	4.5	25
132	Uses of Î²-galactosidase tag in on-line monitoring production of fusion proteins and gene expression in Escherichia coli. Enzyme and Microbial Technology, 1993, 15, 66-71.	3.2	24
133	Distinct mechanisms of antibody-mediated enzymatic reactivation in Î²-galactosidase molecular sensors. FEBS Letters, 1998, 438, 267-271.	2.8	24
134	Engineering tumor cell targeting in nanoscale amyloidal materials. Nanotechnology, 2017, 28, 015102.	2.6	24
135	CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 49.	8.6	24
136	Nonviral Gene Delivery to the Central Nervous System Based on a Novel Integrin-Targeting Multifunctional Protein. Human Gene Therapy, 2003, 14, 1215-1223.	2.7	23
137	Bacterial inclusion bodies: an emerging platform for drug delivery and cell therapy. Nanomedicine, 2012, 7, 1277-1279.	3.3	23
138	Complex Particulate Biomaterials as Immunostimulant-Delivery Platforms. PLoS ONE, 2016, 11, e0164073.	2.5	23
139	ATP hydrolysis during SOS induction in Escherichia coli. Journal of Bacteriology, 1986, 167, 1055-1057.	2.2	22
140	An optimized ultrasonication protocol for bacterial cell disruption and recovery of ?-galactosidase fusion proteins. Biotechnology Letters, 1994, 8, 509.	0.5	22
141	A recombinant, arginine-glycine-aspartic acid (RGD) motif from foot-and-mouth disease virus binds mammalian cells through vitronectin and, to a lower extent, fibronectin receptors. Gene, 1996, 180, 101-106.	2.2	22
142	Amyloid-linked cellular toxicity triggered by bacterial inclusion bodies. Biochemical and Biophysical Research Communications, 2007, 355, 637-642.	2.1	22
143	Friendly production of bacterial inclusion bodies. Korean Journal of Chemical Engineering, 2010, 27, 385-389.	2.7	22
144	Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. Biomaterials, 2010, 31, 9333-9339.	11.4	22

#	Article	IF	Citations
145	Functionalization of 3D scaffolds with protein-releasing biomaterials for intracellular delivery. Journal of Controlled Release, 2013, 171, 63-72.	9.9	22
146	Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A. Applied Microbiology and Biotechnology, 2015, 99, 5863-5874.	3.6	22
147	Selective delivery of T22-PE24-H6 to CXCR4⁺ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model. Theranostics, 2020, 10, 5169-5180.	10.0	22
148	Molecular cloning and expression of the VP1 gene of foot-and-mouth disease virus C1 in E. coli: effect on bacterial cell viability. Applied Microbiology and Biotechnology, 1991, 35, 788-792.	3.6	21
149	Molecular Mechanisms for Antibody-Mediated Modulation of Peptide-Displaying Enzyme Sensors. Biochemical and Biophysical Research Communications, 2000, 275, 360-364.	2.1	21
150	Enhanced response to antibody binding in engineered Î²-galactosidase enzymatic sensors. BBA - Proteins and Proteomics, 2002, 1596, 212-224.	2.1	21
151	Recombinant Fab expression and secretion in Escherichia coli continuous culture at medium cell densities: Influence of temperature. Process Biochemistry, 2012, 47, 446-452.	3.7	21
152	Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles. Nanoscale, 2017, 9, 6427-6435.	5.6	21
153	Protein-driven nanomedicines in oncotherapy. Current Opinion in Pharmacology, 2019, 47, 1-7.	3.5	21
154	Conformational flexibility in a highly mobile protein loop of foot-and-mouth disease virus: distinct structural requirements for integrin and antibody binding 1 1Edited by J. Karn. Journal of Molecular Biology, 1998, 283, 331-338.	4.2	20
155	Rehosting of Bacterial Chaperones for High-Quality Protein Production. Applied and Environmental Microbiology, 2009, 75, 7850-7854.	3.1	20
156	Integrating mechanical and biological control of cell proliferation through bioinspired multieffector materials. Nanomedicine, 2015, 10, 873-891.	3.3	20
157	Functional recruitment for drug delivery through protein-based nanotechnologies. Nanomedicine, 2016, 11, 1333-1336.	3.3	20
158	Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials & Interfaces, 2016, 8, 25741-25752.	8.0	20
159	Insertion of a 27 amino acid viral peptide in different zones ofEscherichia coliÃŽÂ²-galactosidase: Effects on the enzyme activity. FEMS Microbiology Letters, 1994, 123, 107-112.	1.8	19
160	The Biological Potential Hidden in Inclusion Bodies. Pharmaceutics, 2020, 12, 157.	4.5	19
161	Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders. Journal of Extracellular Vesicles, 2021, 10, e12058.	12.2	19
162	Induction of the SOS response by hydroxyurea in Escherichia coli K12. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1987, 192, 105-108.	1.1	18

#	Article	IF	Citations
163	Polylinker-Encoded Peptides Can Confer Toxicity to Recombinant Proteins Produced in Escherichia coli. Biotechnology Progress, 1996, 12, 723-727.	2.6	18
164	Cell lysis in Escherichia coli cultures stimulates growth and biosynthesis of recombinant proteins in surviving cells. Microbiological Research, 2001, 156, 13-18.	5.3	18
165	RGD domains neuroprotect the immature brain by a glialâ€dependent mechanism. Annals of Neurology, 2007, 62, 251-261.	5.3	18
166	Conformational Conversion during Controlled Oligomerization into Nonamylogenic Protein Nanoparticles. Biomacromolecules, 2018, 19, 3788-3797.	5.4	18
167	Integrated approach to produce a recombinant, hisâ€tagged human Î±â€galactosidase a in mammalian cells. Biotechnology Progress, 2011, 27, 1206-1217.	2.6	17
168	Inclusion bodies of fuculoseâ€1â€phosphate aldolase as stable and reusable biocatalysts. Biotechnology Progress, 2012, 28, 421-427.	2.6	17
169	Engineering Protein Nanoparticles Out from Components of the Human Microbiome. Small, 2020, 16, 2001885.	10.0	17
170	Biofabrication of functional protein nanoparticles through simple His-tag engineering. ACS Sustainable Chemistry and Engineering, 2021, 9, 12341-12354.	6.7	17
171	Activated RecA protein may induce expression of a gene that is not controlled by the LexA repressor and whose function is required for mutagenesis and repair of UV-irradiated bacteriophage lambda. Journal of Bacteriology, 1987, 169, 4816-4821.	2.2	16
172	Ammonium-Mediated Reduction of Plasmid Copy Number and Recombinant Gene Expression in Escherichia coli. Biotechnology Progress, 1994, 10, 648-651.	2.6	16
173	RGD-based cell ligands for cell-targeted drug delivery act as potent trophic factors. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1263-1266.	3.3	16
174	A novel bio-functional material based on mammalian cell aggresomes. Applied Microbiology and Biotechnology, 2015, 99, 7079-7088.	3.6	16
175	Protein Nanoparticles Made of Recombinant Viral Antigens: A Promising Biomaterial for Oral Delivery of Fish Prophylactics. Frontiers in Immunology, 2018, 9, 1652.	4.8	16
176	Release of functional fibroblast growth factor-2 from artificial inclusion bodies. Journal of Controlled Release, 2020, 327, 61-69.	9.9	16
177	Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells. International Journal of Nanomedicine, 2021, Volume 16, 1869-1888.	6.7	16
178	GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases. Drug Delivery, 2022, 29, 1384-1397.	5.7	16
179	Title is missing!. Biotechnology Letters, 2002, 24, 1939-1944.	2.2	15
180	Profiling the allosteric response of an engineered Î²-galactosidase to its effector, anti-HIV antibody. Biochemical and Biophysical Research Communications, 2004, 314, 854-860.	2.1	15

#	Article	IF	Citations
181	Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication, 2016, 8, 025001.	7.1	15
182	Endosomal escape of protein nanoparticles engineered through humanized histidine-rich peptides. Science China Materials, 2020, 63, 644-653.	6.3	15
183	Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells. ACS Applied Materials & Interfaces, 2020, 12, 5381-5388.	8.0	15
184	Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4+ head and neck squamous cell carcinoma tumors. Acta Pharmaceutica Sinica B, 2022, 12, 2578-2591.	12.0	15
185	In Situ Proteolytic Digestion of Inclusion Body Polypeptides Occurs as a Cascade Process. Biochemical and Biophysical Research Communications, 2001, 282, 436-441.	2.1	14
186	Efficient Accommodation of Recombinant, Foot-and-Mouth Disease Virus RGD Peptides to Cell-Surface Integrins. Biochemical and Biophysical Research Communications, 2001, 285, 201-206.	2.1	14
187	High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor. Molecular Immunology, 2006, 43, 2119-2123.	2.2	14
188	Nanoparticulate architecture of protein-based artificial viruses is supported by proteinâ€"DNA interactions. Nanomedicine, 2011, 6, 1047-1061.	3.3	14
189	A refined cocktailing of pro-apoptotic nanoparticles boosts anti-tumor activity. Acta Biomaterialia, 2020, 113, 584-596.	8.3	14
190	Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles. Acta Biomaterialia, 2021, 119, 312-322.	8.3	14
191	Reversible activation of a cryptic cleavage site within E. coli Î²-galactosidase in Î²-galactosidase fusion proteins. BBA - Proteins and Proteomics, 1997, 1343, 221-226.	2.1	13
192	Title is missing!. Biotechnology Letters, 1997, 19, 373-378.	2.2	13
193	Analytical Approaches for Assessing Aggregation of Protein Biopharmaceuticals. Current Pharmaceutical Biotechnology, 2011, 12, 1530-1536.	1.6	13
194	Enzymatic characterization of highly stable human alpha-galactosidase A displayed on magnetic particles. Biochemical Engineering Journal, 2012, 67, 20-27.	3.6	13
195	Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli. Microbial Cell Factories, 2016, 15, 59.	4.0	13
196	Self-assembling as regular nanoparticles dramatically minimizes photobleaching of tumour-targeted GFP. Acta Biomaterialia, 2020, 103, 272-280.	8.3	13
197	Engineering the Performance of Artificial Inclusion Bodies Built of Catalytic Î²-Galactosidase. ACS Sustainable Chemistry and Engineering, 2021, 9, 2552-2558.	6.7	13
198	In Vitro Fabrication of Microscale Secretory Granules. Advanced Functional Materials, 2021, 31, 2100914.	14.9	13

#	Article	IF	Citations
199	Changes in ATP Concentration in Escherichia coli during Induction of the SOS System by Mitomycin C and Bleomycin. Microbiology (United Kingdom), 1984, 130, 2247-2251.	1.8	12
200	Protein Aggregation and Soluble Aggregate Formation Screened by a Fast Microdialysis Assay. Journal of Biomolecular Screening, 2010, 15, 453-457.	2.6	12
201	The fusogenic peptide HA2 impairs selectivity of CXCR4-targeted protein nanoparticles. Chemical Communications, 2017, 53, 4565-4568.	4.1	12
202	Engineering multifunctional protein nanoparticles by <i>in vitro</i> disassembling and reassembling of heterologous building blocks. Nanotechnology, 2017, 28, 505102.	2.6	12
203	Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1777-1786.	3.3	12
204	Nanostructured recombinant protein particles raise specific antibodies against the nodavirus NNV coat protein in sole. Fish and Shellfish Immunology, 2020, 99, 578-586.	3.6	12
205	A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. Biomaterials, 2022, 280, 121258.	11.4	12
206	Prediction of transport properties for Lennard-Jones fluids and their binary mixtures using the effective-diameter hard-sphere kinetic theory. Molecular Physics, 1991, 74, 1315-1334.	1.7	11
207	Variable specific activity ofEscherichia coli?-galactosidase in bacterial cells. Biotechnology and Bioengineering, 2001, 72, 255-260.	3.3	11
208	The impact of dnaKJ overexpression on recombinant protein solubility results from antagonistic effects on the control of protein quality. Biotechnology Letters, 2004, 26, 595-601.	2.2	11
209	Intracellular trafficking of a dynein-based nanoparticle designed for gene delivery. European Journal of Pharmaceutical Sciences, 2018, 112, 71-78.	4.0	11
210	Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4+ colorectal cancer. Acta Biomaterialia, 2019, 99, 426-432.	8.3	11
211	Engineering a recombinant chlorotoxin as cell-targeted cytotoxic nanoparticles. Science China Materials, 2019, 62, 892-898.	6.3	11
212	Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles. Nanotechnology, 2019, 30, 115101.	2.6	11
213	Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering. Science China Materials, 2020, 63, 147-156.	6.3	11
214	Aggregation-prone peptides modulate activity of bovine interferon gamma released from naturally occurring protein nanoparticles. New Biotechnology, 2020, 57, 11-19.	4.4	11
215	Potential of MMP-9 based nanoparticles at optimizing the cow dry period: pulling apart the effects of MMP-9 and nanoparticles. Scientific Reports, 2020, 10, 11299.	3.3	11
216	Stable anchoring of bacteria-based protein nanoparticles for surface enhanced cell guidance. Journal of Materials Chemistry B, 2020, 8, 5080-5088.	5.8	11

#	Article	IF	Citations
217	Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4+ Cancers. Cancers, 2021, 13, 2929.	3.7	11
218	Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. Journal of Controlled Release, 2021, 335, 117-129.	9.9	11
219	Bacterial Inclusion Body Purification. Methods in Molecular Biology, 2015, 1258, 293-305.	0.9	11
220	Peptide display on functional tailspike protein of bacteriophage P22. Gene, 1996, 176, 225-229.	2.2	10
221	Tolerance ofEscherichia coli ?-galactosidase C-terminus to different-sized fusions. , 1999, 64, 644-649.		10
222	Protein Inclusion Bodies in Recombinant Bacteria. , 2006, , 237-292.		10
223	CXCR4⁺-targeted protein nanoparticles produced in the food-grade bacterium <i>Lactococcus lactis</i>. Nanomedicine, 2016, 11, 2387-2398.	3.3	10
224	In Vivo Bactericidal Efficacy of GWH1 Antimicrobial Peptide Displayed on Protein Nanoparticles, a Potential Alternative to Antibiotics. Pharmaceutics, 2020, 12, 1217.	4.5	10
225	Ion-dependent slow protein release from <i>inÂvivo</i> disintegrating micro-granules. Drug Delivery, 2021, 28, 2383-2391.	5.7	10
226	ATP Production after ultraviolet irradiation inEscherichia coli. Current Microbiology, 1986, 14, 31-34.	2.2	9
227	Viral spread within ageing bacterial populations. Gene, 1997, 202, 147-149.	2.2	9
228	Insertional Mutagenesis in the Tailspike Protein of Bacteriophage P22. Biochemical and Biophysical Research Communications, 1998, 244, 428-433.	2.1	9
229	Co-production of GroELS discriminates between intrinsic and thermally-induced recombinant protein aggregation during substrate quality control. Microbial Cell Factories, 2011, 10, 79.	4.0	9
230	Disulfide Bond Formation and Activation of Escherichia coli Î²-Galactosidase under Oxidizing Conditions. Applied and Environmental Microbiology, 2012, 78, 2376-2385.	3.1	9
231	Protein nanoparticles are nontoxic, tuneable cell stressors. Nanomedicine, 2018, 13, 255-268.	3.3	9
232	Surface-Bound Gradient Deposition of Protein Nanoparticles for Cell Motility Studies. ACS Applied Materials & Interfaces, 2018, 10, 25779-25786.	8.0	9
233	Nanostructure Empowers Active Tumor Targeting in Ligandâ€Based Molecular Delivery. Particle and Particle Systems Characterization, 2019, 36, 1900304.	2.3	9
234	Recombinant Protein-Based Nanoparticles: Elucidating Their Inflammatory Effects In Vivo and Their Potential as a New Therapeutic Format. Pharmaceutics, 2020, 12, 450.	4.5	9

#	Article	IF	Citations
235	Engineering Protein Venoms as Selfâ€Assembling CXCR4â€Targeted Cytotoxic Nanoparticles. Particle and Particle Systems Characterization, 2020, 37, 2000040.	2.3	9
236	The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies. Pharmaceutics, 2022, 14, 602.	4.5	9
237	Further characterization of the expression of SOS functions in recA430 mutants of Escherichia coli. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1983, 121, 171-175.	1.1	8
238	Simultaneous on line monitoring of intracellular Î²-galactosidase activity and biomass using flow injection analysis inEscherichia coli batch fermentations. Biotechnology Letters, 1992, 6, 213-218.	0.5	8
239	A recombinant foot-and-mouth disease virus antigen inhibits DNA replication and triggers the SOS response inEscherichia coli. FEMS Microbiology Letters, 1995, 129, 157-162.	1.8	8
240	Microheterogeneity of p60 capsid protein and the encoding gene among contemporary isolates of rabbit hemorrhagic disease virus. Virus Genes, 1996, 12, 189-192.	1.6	8
241	Title is missing!. Biotechnology Letters, 1997, 19, 225-228.	2.2	8
242	Antigenicity of VP60 structural proteinof rabbit haemorrhagic disease virus. Archives of Virology, 1997, 142, 1843-1848.	2.1	8
243	Unfolding of bacteriophage P22 tailspike protein: enhanced thermal stability of an N-terminal fusion mutant. FEBS Letters, 1998, 432, 228-230.	2.8	8
244	Corrigendum to: Distinct mechanisms of antibody-mediated enzymatic reactivation in Î²-galactosidase molecular sensors. FEBS Letters, 2000, 473, 123-123.	2.8	8
245	Title is missing!. Biotechnology Letters, 2002, 24, 1543-1551.	2.2	8
246	DnaK/DnaJ-assisted recombinant protein production in Trichoplusia ni larvae. Applied Microbiology and Biotechnology, 2010, 86, 633-639.	3.6	8
247	Recombinant protein quality evaluation: proposal for a minimal information standard. Standards in Genomic Sciences, 2011, 5, 195-197.	1.5	8
248	Subcutaneous preconditioning increases invasion and metastatic dissemination in colorectal cancer models. DMM Disease Models and Mechanisms, 2014, 7, 387-96.	2.4	8
249	Formulating tumor-homing peptides as regular nanoparticles enhances receptor-mediated cell penetrability. Materials Letters, 2015, 154, 140-143.	2.6	8
250	Selecting Subpopulations of High-Quality Protein Conformers among Conformational Mixtures of Recombinant Bovine MMP-9 Solubilized from Inclusion Bodies. International Journal of Molecular Sciences, 2021, 22, 3020.	4.1	8
251	Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials. ACS Applied Materials & Interfaces, 2021, 13, 29406-29415.	8.0	8
252	Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines. Acta Biomaterialia, 2021, 130, 211-222.	8.3	8

#	Article	IF	Citations
253	Time-Prolonged Release of Tumor-Targeted Proteinâ€“MMAE Nanoconjugates from Implantable Hybrid Materials. Pharmaceutics, 2022, 14, 192.	4.5	8
254	A cell adhesion peptide from foot-and-mouth disease virus can direct cell targeted delivery of a functional enzyme. , 1998, 59, 294-301.		7
255	Display-Induced Antigenic Variation in Recombinant Peptides. Biochemical and Biophysical Research Communications, 1998, 248, 773-777.	2.1	7
256	Enhanced molecular recognition signal in allosteric biosensing by proper substrate selection. Biotechnology and Bioengineering, 2006, 94, 193-199.	3.3	7
257	Discriminating Foot-and-Mouth Disease Virus-Infected and Vaccinated Animals by Use of Î²-Galactosidase Allosteric Biosensors. Vaccine Journal, 2009, 16, 1228-1235.	3.1	7
258	How to break recombinant bacteria: Does it matter?. Bioengineered Bugs, 2011, 2, 222-225.	1.7	7
259	Polyethylenimine-polyethyleneglycol-bis(aminoethylphosphate) nanoparticles mediated efficient DNA and siRNA transfection in mammalian cells. Soft Matter, 2011, 7, 6103.	2.7	7
260	Targeting in Cancer Therapies. Medical Sciences (Basel, Switzerland), 2016, 4, 6.	2.9	7
261	High-Throughput Cell Motility Studies on Surface-Bound Protein Nanoparticles with Diverse Structural and Compositional Characteristics. ACS Biomaterials Science and Engineering, 2019, 5, 5470-5480.	5.2	7
262	Efficient bioactive oligonucleotideâ€protein conjugation for cellâ€targeted cancer therapy. ChemistryOpen, 2019, 8, 382-387.	1.9	7
263	Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. Journal of Controlled Release, 2022, 343, 277-287.	9.9	7
264	Induced mutagenesis by bleomycin in the purple sulfur bacterium Thiocapsa roseopersicina. Current Microbiology, 1995, 30, 117-120.	2.2	6
265	A recombinant foot-and-mouth disease virus antigen inhibits DNA replication and triggers the SOS response in. FEMS Microbiology Letters, 1995, 129, 157-162.	1.8	6
266	Distinct chaperone affinity to folding variants of homologous recombinant proteins. Biotechnology Letters, 1999, 21, 531-536.	2.2	6
267	Detection of Molecular Interactions by Using a New Peptide-Displaying Bacteriophage Biosensor. Biochemical and Biophysical Research Communications, 1999, 262, 801-805.	2.1	6
268	Overexpression of the nuclear factor kappaB inhibitor A20 is neurotoxic after an excitotoxic injury to the immature rat brain. Neurological Research, 2013, 35, 308-319.	1.3	6
269	Comparative analysis of lentiviral vectors and modular protein nanovectors for traumatic brain injury gene therapy. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14047.	4.1	6
270	Developing Proteinâ€“Antitumoral Drug Nanoconjugates as Bifunctional Antimicrobial Agents. ACS Applied Materials & Interfaces, 2020, 12, 57746-57756.	8.0	6

#	Article	IF	Citations
271	Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease. Biomedicines, 2022, 10, 1680.	3.2	6
272	Effect of Adenine, Cytidine and Guanosine on the Expression of the SOS System in Escherichia coli. Microbiology (United Kingdom), 1985, 131, 113-118.	1.8	5
273	RecA-dependent viral burst in bacterial colonies during the entry into stationary phase. FEMS Microbiology Letters, 1999, 170, 313-317.	1.8	5
274	RecA-dependent viral burst in bacterial colonies during the entry into stationary phase. FEMS Microbiology Letters, 1999, 170, 313-317.	1.8	5
275	Successful mimicry of a complex viral antigen by multiple peptide insertions in a carrier protein. FEBS Letters, 2000, 474, 87-92.	2.8	5
276	Connection between gene dosage and protein stability revealed by a high-yield production of recombinant proteins in anE. coli LexA1(Ind?) background. Biotechnology and Bioengineering, 2002, 78, 722-730.	3.3	5
277	Tailoring molecular sensing for peptide displaying engineered enzymes. Biotechnology Letters, 2002, 24, 469-477.	2.2	5
278	Engineering ofEscherichia coliÎ²-galactosidase for solvent display of a functional scFv antibody fragment. FEBS Letters, 2003, 533, 115-118.	2.8	5
279	A mathematical approach to molecular organization and proteolytic disintegration of bacterial inclusion bodies. Mathematical Medicine and Biology, 2005, 22, 209-226.	1.2	5
280	Analysis of recombinant protein toxicity in E. coli through a phage Î»-based genetic screening system. Biotechnology Letters, 2007, 29, 1381-1386.	2.2	5
281	Screening HIVâ€1 antigenic peptides as receptors for antibodies and CD4 in allosteric nanosensors. Journal of Molecular Recognition, 2009, 22, 255-260.	2.1	5
282	Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4. Pharmaceutics, 2021, 13, 1922.	4.5	5
283	A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model. Pharmaceutics, 2022, 14, 887.	4.5	5
284	Indirect induction of SOS functions in Salmonella typhimurium. Antonie Van Leeuwenhoek, 1983, 49, 471-484.	1.7	5
285	Conditions for a continuous production of transient microbial products in a two-stage fermentation system. Biotechnology Letters, 1993, 15, 827.	2.2	4
286	Inhibition of CI857-controlled recombinant gene expression in Escherichia coli at very low concentrations of glucose. Biotechnology Letters, 1993, 15, 549-552.	2.2	4
287	Converging antigenic structure of a recombinant viral peptide displayed on different frameworks of carrier proteins. FEBS Letters, 1996, 397, 169-172.	2.8	4
288	Heat-inactivation of plasmid-encoded CI857 repressor induces gene expression from IndÃ¢Â^Â'lambda prophage in recombinantEscherichia coli. FEMS Microbiology Letters, 1999, 177, 327-334.	1.8	4

#	Article	IF	Citations
289	Antiretroviral Therapy-Induced Functional Modification of IgG4 and IgM Responses in HIV-1â€“Infected Individuals Screened by an Allosteric Biosensor. Journal of Biomolecular Screening, 2008, 13, 817-821.	2.6	4
290	Interleukinâ€10 overexpression does not synergize with the neuroprotective action of RGDâ€containing vectors after postnatal brain excitotoxicity but modulates the main inflammatory cell responses. Journal of Neuroscience Research, 2012, 90, 143-159.	2.9	4
291	Improving Biomaterials Imaging for Nanotechnology: Rapid Methods for Protein Localization at Ultrastructural Level. Biotechnology Journal, 2018, 13, e1700388.	3.5	4
292	Title: insoluble proteins catch heterologous soluble proteins into inclusion bodies by intermolecular interaction of aggregating peptides. Microbial Cell Factories, 2021, 20, 30.	4.0	4
293	A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice. Biomedicine and Pharmacotherapy, 2022, 150, 112940.	5.6	4
294	An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials. International Journal of Molecular Sciences, 2022, 23, 4958.	4.1	4
295	Evidence for a specific regulation of recA gene transcription in Escherichia coli. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1988, 199, 123-130.	1.0	3
296	Assay of ?-galactosidase activity by Flow Injection Analysis (FIA). Biotechnology Letters, 1991, 5, 389.	0.5	3
297	Peptide insertions in ?-galactosidase activating interface can improve binding in TPEG-Sepharose affinity chromatography. Biotechnology Letters, 1995, 9, 767-770.	0.5	3
298	The expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response inEscherichia coli. , 1999, 64, 127-127.		3
299	Old bugs for new tasks; the microbial offer in the proteomics era. Microbial Cell Factories, 2002, 1, 4.	4.0	3
300	Engineering the E. coli Î²-galactosidase for the screening of antiviral protease inhibitors. Biochemical and Biophysical Research Communications, 2005, 329, 453-456.	2.1	3
301	Allosteric molecular sensing of anti-HIV antibodies by an immobilized engineered Î²-galactosidase. Enzyme and Microbial Technology, 2007, 41, 492-497.	3.2	3
302	The scientific impact of microbial cell factories. Microbial Cell Factories, 2008, 7, 33.	4.0	3
303	Variable specific activity of Escherichia coli beta-galactosidase in bacterial cells. Biotechnology and Bioengineering, 2001, 72, 255-60.	3.3	3
304	The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles. Science China Materials, 2022, 65, 1662-1670.	6.3	3
305	Production of thermally induced recombinant proteins relative to cell biomass is influenced by cell density in Escherichia coli batch cultures. Biotechnology Letters, 1994, 16, 777-782.	2.2	2
306	Antigenicity of a viral peptide displayed on ÃŽÂ²-galactosidase fusion proteins is influenced by the presence of the homologous partner protein. FEMS Microbiology Letters, 1996, 145, 77-82.	1.8	2

#	Article	IF	Citations
307	Plasmid maintenance and recombinant cell fitness explored in bacterial colonies. Biotechnology Letters, 2001, 23, 831-838.	2.2	2
308	Recombinant protein production in the new Millennium. Microbial Cell Factories, 2007, 6, 33.	4.0	2
309	Effect of the DnaK chaperone on the conformational quality of JCV VP1 virusâ€like particles produced in <i>Escherichia coli</i>. Biotechnology Progress, 2014, 30, 744-748.	2.6	2
310	Targeting low-density lipoprotein receptors with protein-only nanoparticles. Journal of Nanoparticle Research, 2015, 17, 1.	1.9	2
311	Protein Inclusion Bodies in Recombinant Bacteria. , 2006, , 237-292.		2
312	Cell death induced by phage at high multiplicity of infection is not due to lysis inSalmonella typhimurium. FEMS Microbiology Letters, 1982, 15, 291-294.	1.8	1
313	Expression of the SOS system in Escherichia coli growing under nitrate respiration conditions. Antonie Van Leeuwenhoek, 1986, 52, 63-74.	1.7	1
314	A model for continuous production of thermally induced recombinant proteins. Biotechnology Letters, 1991, 13, 249-254.	2.2	1
315	Transport properties in dense fluids and their binary mixtures. Fluid Phase Equilibria, 1992, 79, 277-288.	2.5	1
316	SOS system induction in Escherichia coli cells with distinct levels of ribonucleotide reductase activity. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1992, 281, 137-141.	1.1	1
317	A new editorial board for a new editorial period. Microbial Cell Factories, 2004, 3, 3.	4.0	1
318	Comparative analysis of E. coli inclusion bodies and thermal protein aggregates. Microbial Cell Factories, 2006, 5, P16.	4.0	1
319	Systems-Level Analysis of Protein Quality in Inclusion Body-Forming Escherichia coli Cells. , 2009, , 295-326.		1
320	Improved performance of proteinâ€based recombinant gene therapy vehicles by tuning downstream procedures. Biotechnology Progress, 2013, 29, 1458-1463.	2.6	1
321	Annual acknowledgement of manuscript reviewers. Microbial Cell Factories, 2014, 13, 18.	4.0	1
322	The Potential of Metalloproteinase-9 Administration to Accelerate Mammary Involution and Boost the Immune System at Dry-Off. Animals, 2021, 11, 3415.	2.3	1
323	Toxicity Profiling of Bacterial Inclusion Bodies in Human Caco-2 Cells. Frontiers in Bioengineering and Biotechnology, 2022, 10, 842256.	4.1	1
324	Effect of P22-mediated Receptor Release and of Phage DNA Injection on Cell Viability of Salmonella typhimurium. Journal of General Virology, 1986, 67, 2561-2564.	2.9	0

#	ARTICLE	IF	CITATIONS
325	Evidence for a specific regulation of recA gene transcription in Escherichia coli. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1988, 199, 123-130.	0.4	0
326	Mitomycin C stimulates thermally induced recombinant gene expression in Escherichia coli MC strains. Applied Microbiology and Biotechnology, 1995, 42, 890-894.	3.6	0
327	Phage spread dynamics in clonal bacterial populations is depending on features of the founder cell. Microbiological Research, 2001, 156, 35-40.	5.3	0
328	Focusing in bioproduction science. Microbial Cell Factories, 2005, 4, 10.	4.0	0
329	Cellular toxicity triggered by bacterial inclusion bodies. Microbial Cell Factories, 2006, 5, P9.	4.0	0
330	Title is missing!. Microbial Cell Factories, 2006, 5, P43.	4.0	0
331	Performance of beta-galactosidase inclusion bodies in enzymatic bioprocesses. Microbial Cell Factories, 2006, 5, P14.	4.0	0
332	Bacterial inclusion bodies as novel functional and biocompatible nanomaterials. New Biotechnology, 2009, 25, S27.	4.4	0
333	Integrated Approach to Optimize Transient Gene Expression in Mammalian Cells: Production of a Recombinant Human Alpha-galactosidase A. Journal of Biotechnology, 2010, 150, 436-437.	3.8	0
334	Cross-system excision of chaperone-mediated proteolysis in chaperone-assisted recombinant protein production. Bioengineered Bugs, 2010, 1, 148-150.	1.7	0
335	Preface. Progress in Molecular Biology and Translational Science, 2011, 104, xv-xvi.	1.7	0
336	Nanopills: Functional Inclusion Bodies Produced in Bacteria as Naturally Occurring Nanopills for Advanced Cell Therapies (Adv. Mater. 13/2012). Advanced Materials, 2012, 24, 1741-1741.	21.0	0
337	Annual acknowledgement of manuscript reviewers. Microbial Cell Factories, 2015, 14, 34.	4.0	0
338	Engineering bacterial inclusion bodies as nanostructured depots of functional protein drugs. New Biotechnology, 2016, 33, S149.	4.4	0
339	Tolerability to non-endosomal, micron-scale cell penetration probed with magnetic particles. Colloids and Surfaces B: Biointerfaces, 2021, 208, 112123.	5.0	0
340	Polylactide, Processed by a Foaming Method Using Compressed Freon R134a, for Tissue Engineering. Polymers, 2021, 13, 3453.	4.5	0
341	Proteine Bolognese. Modelling in Science Education and Learning, 0, 4, 159.	0.2	0
342	Abstract 2645: Preclinical validation of Myc inhibition by a new generation of Omomyc-based inhibitors. , 2015, , .		0